In a major discovery, scientists have presented the first evidence of Alzheimer's disease transmission in living individuals.

Alongside beta-amyloid, the second major target of drugs in development for Alzheimer's is the tau protein, responsible for ...

And also we found the significant effects in terms of ADAS-Cog [Alzheimer's Disease Assessment Scale-Cognitive Subscale], ...

This focus could potentially offer a more effective and safer treatment for Alzheimer’s, addressing a critical need ... is a subclass monoclonal antibody which selectively targets amyloid-beta ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Acumen Pharmaceuticals, Inc. ( (ABOS) ) has released its Q3 earnings. Here is a breakdown of the information Acumen Pharmaceuticals, Inc.

The availability of amyloid-reducing therapies now makes detection of Alzheimer's disease in its early stages critical, ...

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

But poor sleep is both a risk factor for and a symptom of Alzheimer's disease, making it tricky to tease apart cause and ...

We asked Dr. Joanne Pike, CEO of the Alzheimer's Association to help explain the challenges and hopes when it comes to this debilitating disease.

Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.

The drug works by removing accumulated amyloid beta proteins in the brain ... Kisunla will join lecanemab as an option for ...